The top management of Sun Pharmaceutical Industries is going to see a lot of changes. The company has appointed Kirti Ganorkar as the new managing director. He will take over this responsibility from September 1 2025 replacing Dilip Sanghvi. The pharmaceutical company said in a statement that the entire business and all functions will work under the supervision of Ganorkar. At the same time Dilip Sanghvi will continue to chair the companys board as executive chairman. Ganorkars appointment as MD is subject to shareholder approval at Sun Pharmas upcoming annual general meeting. Ganorkar has been leading the India business at Sun Pharma since June 2019. Under his leadership the companys India business has grown steadily further increasing its market share. Prior to this Ganorkar has held several leadership roles in the company across business development marketing mergers and acquisitions new product introductions project management IP and litigation. According to Sun Pharma Ganorkar has played a key role in the companys entry into the specialty sector by acquiring rights to innovative products like Ilumya. He led the companys entry into Japan and laid the initial base for its entry into Europe. Ganorkar who holds a degree in chemical engineering and an MBA joined Sun Pharma in 1996. He also supported the US business along with steering several large generic projects from concept to commercialization. The company said Sanghvi will focus on strengthening the companys specialty portfolio.